Back to search results

Algorithm- and Team-Supported Lipid Management for Heart Disease

This study is testing a new way to manage high cholesterol (hyperlipidemia) in people with atherosclerotic cardiovascular disease (ASCVD), a condition where plaque builds up in your arteries. It compares an "algorithm- and multi-professional team-supported lipid management" strategy against the usual care you'd get from your doctor. The goal is to see if the new strategy can better lower your "bad" cholesterol (LDL-C). You might be able to join if you are over 18 and have documented ASCVD. The study will measure the change in your LDL-C levels from the start to 3 months later. The current status of this study is unclear, and it plans to enroll about 100 participants.

Study design
This is a randomized, controlled study, meaning participants are assigned by chance to one of two groups. Approximately 100 participants will be included.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at 3 months after baseline.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07334834

Implementation of an Algorithm- and Multi-professional Team-supported Strategy to Improve Lipid Management of Patients With Atherosclerotic Cardiovascular Disease

Recruiting
NAAges 18+InterventionalTreatment
Colorado Prevention Center
~100 participants
Updated 2026-01-23 on ClinicalTrials.gov
What's tested:Algorithm- and multi-professional team-supported lipid managementGuideline-directed lipid management by usual care provider

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The between group difference in LDL-C percent change
Measured over Baseline to 3 months

Conditions

Hyperlipidemia

Explore related trials

AtherosclerosisCarotid Artery DisorderCoronary Artery DiseasePeripheral Artery Disease

Where it's being run

1 sites across 1 states
Colorado1

Study leadership

  • Marc Bonaca, MD · PRINCIPAL_INVESTIGATOR · Colorado Prevention Center

Who to contact

Marc Bonaca, MD
[email protected]
(303) 860-9900
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Provided informed consent
Age \>18 years inclusive at screening
Documented atherosclerotic vascular disease including:
Coronary artery disease (prior revascularization, myocardial infarction, imaging evidence of coronary atherosclerosis)
Peripheral artery disease (prior revascularization, amputation, ankle: brachial index (ABI) ≤ 0.90, imaging evidence of extra-coronary atherosclerosis)
Carotid artery disease (prior endarterectomy or stenting of the extracranial carotid artery or imaging evidence of carotid atherosclerosis)
Imaging evidence of atherosclerotic vascular disease in a non-coronary vascular bed (e.g. aorta, mesenteric, renal)
LDL-C \>70mg/dL

Exclusion

Any reason that, in the opinion of the investigator, the patient would be unable to adhere to the protocol for the duration of the study (e.g. terminal diagnosis, metastatic cancer) or in whom participation might result in harm.
Planned active titration of current lipid-lowering therapy
Myocardial infarction or arterial revascularization within prior 30 days

What this trial measures

  • The between group difference in LDL-C percent changeBaseline to 3 months